MedPath

Perrigo

🇮🇪Ireland
Ownership
Private
Employees
9.1K
Market Cap
$3.9B
Website
Introduction

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Comparative Study for the Evaluation of Two Medical Devices on the Treatment of Head Lice Infestation

Not Applicable
Recruiting
Conditions
Head Lice Infestation
Interventions
Device: Paranix® Lotion
Device: Paranix® Shampoo
First Posted Date
2023-09-28
Last Posted Date
2023-09-28
Lead Sponsor
Perrigo CSCI
Target Recruit Count
136
Registration Number
NCT06057506
Locations
🇲🇺

Insight Research, Quatre Bornes, Mauritius

Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation

Not Applicable
Conditions
Head Lice
Interventions
Other: INVESTIGATIONAL DEVICE
Other: Comparator device
First Posted Date
2022-05-18
Last Posted Date
2022-06-01
Lead Sponsor
Perrigo CSCI
Target Recruit Count
136
Registration Number
NCT05379114
Locations
🇲🇺

Céline Lhéritier, Quatre Bornes, Mauritius

Effects of Arterin Cholesterol for Reduction of Lipid Levels

Not Applicable
Conditions
Blood Cholesterol Lowers
LDL-C
Interventions
Dietary Supplement: High Dose Arterin Cholesterol
Dietary Supplement: Low Dose Arterin Cholesterol
Dietary Supplement: Placebo
First Posted Date
2021-02-11
Last Posted Date
2021-02-11
Lead Sponsor
Perrigo CSCI
Target Recruit Count
114
Registration Number
NCT04749784
Locations
🇩🇪

analyze & realize GmbH, Berlin, Germany

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

Not Applicable
Completed
Conditions
Overweight
Obesity
Interventions
Dietary Supplement: IQP-AE-103
Dietary Supplement: Placebo
First Posted Date
2019-09-12
Last Posted Date
2023-11-28
Lead Sponsor
Perrigo CSCI
Target Recruit Count
178
Registration Number
NCT04086797
Locations
🇩🇪

analyze & realize GmbH, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath